Compare BWAY & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWAY | DNA |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.7M | 458.6M |
| IPO Year | 2011 | 2020 |
| Metric | BWAY | DNA |
|---|---|---|
| Price | $13.42 | $11.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $13.25 | $8.50 |
| AVG Volume (30 Days) | 75.3K | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | $309.69 | N/A |
| Revenue Next Year | $26.21 | N/A |
| P/E Ratio | $81.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.77 | $5.37 |
| 52 Week High | $26.63 | $17.58 |
| Indicator | BWAY | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 74.97 |
| Support Level | $11.90 | $7.57 |
| Resistance Level | $14.83 | N/A |
| Average True Range (ATR) | 0.54 | 0.79 |
| MACD | 0.00 | 0.45 |
| Stochastic Oscillator | 22.30 | 98.77 |
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.